Cargando…

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity

Neutralizing antibodies (inhibitors) to replacement Factor-VIII impair the effective management of hemophilia-A(1). Individuals with hemophilia-A due to major F8 gene disruptions lack antigenically cross-reactive material in their plasma (CRM-negative) and prevalence of inhibitors is >60%. Conver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, Gouri Shankar, Yanover, Chen, Miller-Jenkins, Lisa M., Garfield, Susan, Cole, Shelley A., Curran, Joanne E., Moses, Eric K., Rydz, Natalia, Simhadri, Vijaya, Kimchi-Sarfaty, Chava, Lillicrap, David, Viel, Kevin, Przytycka, Teresa M., Pierce, Glenn F., Howard, Tom E., Sauna, Zuben E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123441/ https://www.ncbi.nlm.nih.gov/pubmed/24037092 http://dx.doi.org/10.1038/nm.3270

Ejemplares similares

Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene
por: Sarachana, Tewarit, et al.
Publicado: (2015)

Recent advances in (therapeutic protein) drug development
por: Lagassé, H.A. Daniel, et al.
Publicado: (2017)

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset
por: McGill, Joseph R., et al.
Publicado: (2021)

Role of microRNAs in Hemophilia and Thrombosis in Humans
por: Jankowska, Katarzyna I., et al.
Publicado: (2020)

Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies
por: Salari, Raheleh, et al.
Publicado: (2013)

A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-A
por: Howard, Tom, et al.
Publicado: (2023)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Characterization of Conformation-Sensitive Antibodies to ADAMTS13, the von Willebrand Cleavage Protease
por: Sauna, Zuben E., et al.
Publicado: (2009)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
por: Simhadri, Vijaya L., et al.
Publicado: (2018)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4(+) T-effector responses to multiple epitopes in FVIII
por: Gunasekera, Devi, et al.
Publicado: (2023)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
por: Swystun, Laura L, et al.
Publicado: (2023)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T-cells
por: Simhadri, Vijaya L., et al.
Publicado: (2021)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Detection of Intracellular Factor VIII Protein in Peripheral Blood Mononuclear Cells by Flow Cytometry
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

A Foundational Study for Normal F8-Containing Mouse Models for the miRNA Regulation of Hemophilia A: Identification and Analysis of Mouse miRNAs that Downregulate the Murine F8 Gene
por: Jankowska, Katarzyna I., et al.
Publicado: (2020)

Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery
por: Hoinka, Jan, et al.
Publicado: (2015)

Aptamers as a Sensitive Tool to Detect Subtle Modifications in Therapeutic Proteins
por: Zichel, Ran, et al.
Publicado: (2012)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Identification of FVIII gene mutations in patients with hemophilia A using new combinatorial sequencing by hybridization
por: Chetta, M., et al.
Publicado: (2008)

Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies
por: Alexaki, Aikaterini, et al.
Publicado: (2019)

Characterization of Coding Synonymous and Non-Synonymous Variants in ADAMTS13 Using Ex Vivo and In Silico Approaches
por: Edwards, Nathan C., et al.
Publicado: (2012)

Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
por: Pratt, Kathleen P., et al.
Publicado: (2022)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019)

A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection
por: McGill, Joseph R., et al.
Publicado: (2022)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Development of an FVIII Inhibitor in a Mild Hemophilia Patient with a Phe595Cys Mutation
por: Yamanouchi, Jun, et al.
Publicado: (2018)

Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services
por: Oudat, Raida, et al.
Publicado: (2020)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
por: Zimta, Alina-Andreea, et al.
Publicado: (2021)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs
por: Becker-Gotot, Janine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_afpos2e2iu5k5mtf1ni5c6b9ub